Recent News

  • Aga to be highighted at UB's first Spotlight Symposia Series
    10/22/24
    The College of Arts and Sciences Spotlight Symposia Series recognizes and elevates members of our faculty. Each Spotlight Symposia honors a particular faculty member by inviting distinguished speakers to our campus who share the honoree’s research field. The symposia places our honoree at the center of vital national and international conversations and serves as an important venue for building scholarly relationships critical to the university. 
  • Thinking about applying to graduate school in Chemistry, Chemical Biology or Medicinal Chemistry?
    10/15/24
    Join us for a virtual information session about graduate school opportunitunies in the Department of Chemistry at the University at Buffalo on Saturday, November 16, 2024 at 12:00 pm. A general overview of our graduate program will be from 12-1 pm followed by:
  • Prof. Luis Colón featured with C&EN’s trailblazers for efforts to increase diversity in the chemical sciences.
    9/24/24
    Prof. Luis Colón has been prominently featured and interviewed in Chemical & Engineering News (the weekly publication of the ACS) for his career-long achievements in scientific mentoring and scholarship, particularly for his efforts to promote diversity within the chemical sciences. Read more about Prof. Colón and his interview with C&EN.
  • Prof. Luis Colón mentioned alongside actors, an NBA player, and others as a part of “The Latino 10”
    9/19/24
    NBC news included Prof. Luis Colón in a star-powered list of Latino decedents in the US entitled “The Latino 10: A standout year.” The piece highlights 10 Americans that have had an outstanding year of national recognition and growth with their Hispanic heritage intrinsically tied to their work. Read about this story.
  • UB Chemistry and Oncology Join Forces to Combat Kidney Cancer
    9/16/24
    Dr. Roberto Pili, MD (Hematology/Oncology) and Dr. David Heppner, PhD (Chemistry) have teamed up to develop treatments against an aggressive form of kidney cancer. The project has been awarded a five-year $1.8M NIH R01 National Cancer Institute R01 shared between the collaborating labs to advance drug discovery in a cancer type where limited therapeutic options are available. Read more about this collaborative work.